Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: August 29, 2023 (Event Date: August 23, 2023)
Context: The Company, incorporated in Delaware with principal offices in Australia, entered into a material definitive agreement to raise capital through a private placement of a convertible redeemable promissory note.
Key Financial Metrics and Transaction Details
- Instrument: 8% Convertible Redeemable Promissory Note.
- Principal Amount: $77,500.
- Proceeds Received: $72,500 (issued at a discount).
- Interest Rate: 8% per annum (increases to 24% upon default).
- Maturity Date: February 23, 2024.
- Use of Proceeds: General working capital purposes.
- Conversion Price: Initial fixed price of $0.04 per share, subject to reduction to $0.02 if the market price trades below $0.03 for five consecutive trading days.
- Prepayment Terms: Company may prepay within 180 days at a premium ranging from 110% to 125% of the face amount plus accrued interest; no prepayment right exists after 180 days.
Material Changes and Terms
This filing represents a new debt obligation and potential equity dilution. Key terms include:
- Conversion Mechanics: Principal and interest are convertible into common stock at the investor's option. In the event of default, the conversion price resets to the lowest trading price of the prior ten trading days.
- Redemption Trigger: Upon a sale of substantially all assets or certain mergers, the investor may request redemption at 150% of principal and accrued interest or immediate conversion.
- Default Penalties: Failure to maintain OTC market listing or a "bid" price increases the outstanding principal by 20%.
- Reserve Requirement: The Company must maintain a reserve of at least 400% of the number of potential conversion shares.
Guidance, Risks, and Contingencies
Risks and Contingencies:
- Dilution Risk: The note includes a beneficial ownership limitation of 4.99% (increasable to 9.9%) and complex conversion pricing that could significantly dilute existing shareholders if the stock price declines.
- Liquidity and Default Risk: The Company faces immediate default if it fails to maintain its OTC listing or reporting requirements. Default triggers a 24% interest rate and potential principal increase.
- Prepayment Constraints: The Company loses the right to prepay the note after 180 days, locking in the debt obligation until maturity.
- Par Value Adjustment: If the conversion price falls below the par value ($0.001), the Company must reduce par value or conduct a reverse stock split.
Management Commentary: The filing does not provide specific forward-looking guidance beyond the stated intent to use proceeds for general working capital.
Investor Verification Checklist
- Verify the current market price of Propanc Biopharma common stock to determine if the conversion price has already adjusted to the $0.02 floor.
- Confirm the Company's current listing status on OTC markets to assess immediate default risk regarding the "bid" price requirement.
- Review the Company's cash position to evaluate the ability to service the 8% interest (payable in stock) and potential prepayment premiums.
- Check for any subsequent filings regarding the issuance of shares upon conversion or further debt instruments with similar terms.